Literature DB >> 27197945

The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.

J S Fowles1,2, D D Dailey1,2, D L Gustafson1,2,3, D H Thamm1,2,3, D L Duval1,2,3.   

Abstract

Mammalian cell tissue culture has been a critical tool leading to our current understanding of cancer including many aspects of cellular transformation, growth and response to therapies. The current use of large panels of cell lines with associated phenotypic and genotypic information now allows for informatics approaches and in silico screens to rapidly test hypotheses based on simple as well as complex relationships. Current cell line panels with large amounts of associated drug sensitivity and genomics data are comprised of human cancer cell lines (i.e. NCI60 and GDSC). There is increased recognition of the contribution of canine cancer to comparative cancer research as a spontaneous large animal model with application in basic and translational studies. We have assembled a panel of canine cancer cell lines to facilitate studies in canine cancer and report here phenotypic and genotypic data associated with these cells.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  canine cancer; cell line panel; comparative oncology; doxorubicin; drug sensitivity; gene expression; microRNA

Mesh:

Substances:

Year:  2016        PMID: 27197945      PMCID: PMC5656225          DOI: 10.1111/vco.12192

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  28 in total

1.  The outgrowth of the nerve fiber as a mode of protoplasmic movement.

Authors:  R G HARRISON
Journal:  J Exp Zool       Date:  1959 Oct-Dec

2.  Drug discovery: Cell lines battle cancer.

Authors:  John N Weinstein
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

3.  Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines.

Authors:  E L Seiser; R Thomas; K L Richards; M Kathryn Kelley; P Moore; S E Suter; M Breen
Journal:  Vet Comp Oncol       Date:  2011-11-23       Impact factor: 2.613

4.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

5.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

6.  Masitinib is safe and effective for the treatment of canine mast cell tumors.

Authors:  K A Hahn; G Ogilvie; G Oglivie; T Rusk; P Devauchelle; A Leblanc; A Legendre; B Powers; P S Leventhal; J-P Kinet; F Palmerini; P Dubreuil; A Moussy; O Hermine
Journal:  J Vet Intern Med       Date:  2008-09-24       Impact factor: 3.333

7.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

8.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

9.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

10.  Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix.

Authors:  W F SCHERER; J T SYVERTON; G O GEY
Journal:  J Exp Med       Date:  1953-05       Impact factor: 14.307

View more
  19 in total

1.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

Review 2.  Barking up the right tree: advancing our understanding and treatment of lymphoma with a spontaneous canine model.

Authors:  Dania Villarnovo; Angela L McCleary-Wheeler; Kristy L Richards
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

3.  In-vitro effects of taurolidine alone and in combination with mitoxantrone and/or piroxicam on canine transitional cell carcinoma.

Authors:  Brittney Byer; Lisa J Schlein; Barbara Rose; Bernard Séguin
Journal:  Can J Vet Res       Date:  2020-04       Impact factor: 1.310

4.  Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.

Authors:  Sunetra Das; Rupa Idate; Daniel P Regan; Jared S Fowles; Susan E Lana; Douglas H Thamm; Daniel L Gustafson; Dawn L Duval
Journal:  Commun Biol       Date:  2021-10-11

5.  In vitro and in vivo activity of liposome-encapsulated curcumin for naturally occurring canine cancers.

Authors:  Sita S Withers; Daniel York; Eric Johnson; Sami Al-Nadaf; Katherine A Skorupski; Carlos O Rodriguez; Jenna H Burton; Teri Guerrero; Kriste Sein; Luke Wittenburg; Robert B Rebhun
Journal:  Vet Comp Oncol       Date:  2018-08-08       Impact factor: 2.613

6.  Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma.

Authors:  Daniel L Gustafson; Keagan P Collins; Jared S Fowles; E J Ehrhart; Kristen M Weishaar; Sunetra Das; Dawn L Duval; Douglas H Thamm
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-14       Impact factor: 3.333

7.  Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.

Authors:  Daniel P Regan; Lyndah Chow; Sunetra Das; Laurel Haines; Eric Palmer; Jade N Kurihara; Jonathan W Coy; Alissa Mathias; Douglas H Thamm; Daniel L Gustafson; Steven W Dow
Journal:  Clin Cancer Res       Date:  2022-02-15       Impact factor: 13.801

8.  Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome.

Authors:  Lauren N Alfino; Kai C Wilczewski-Shirai; Kathryn E Cronise; Jonathan Coy; Kristina Glapa; E J Ehrhart; Joseph B Charles; Dawn L Duval; Daniel P Regan
Journal:  Vet Pathol       Date:  2021-03-09       Impact factor: 3.157

9.  The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.

Authors:  Fernando Alegre; Amanda R Ormonde; Dayn R Godinez; Anuradha Illendula; John H Bushweller; Luke A Wittenburg
Journal:  Vet Comp Oncol       Date:  2019-08-22       Impact factor: 2.613

10.  Genomic and Transcriptomic Characterization of Canine Osteosarcoma Cell Lines: A Valuable Resource in Translational Medicine.

Authors:  Cecilia Gola; Diana Giannuzzi; Andrea Rinaldi; Selina Iussich; Paola Modesto; Emanuela Morello; Paolo Buracco; Luca Aresu; Raffaella De Maria
Journal:  Front Vet Sci       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.